论文部分内容阅读
目的：比较国产天新利博与法国产ｔｉｃｌｏｐｉｄｉｎｅ对冠心病患者血小板聚集率的影响及对心绞痛的疗效。方法：对稳定性心绞痛５０例，应用双盲随机平行对照方法。Ａ组服天新利搏２５０ｍｇ，Ｂ组服ｔｉｃｌｏｐｉｄｉｎｅ２５０ｍｇ，Ｃ组服用安慰剂，均与早餐同服。服药前后检测ＡＤＰ（０５ｍｏｌ／Ｌ，１０ｍｏｌ／Ｌ）诱发的血小板聚集率，６ＫｅｔｏＰＧＦ１２，ＴＸＢ２，血Ｒｔ，出凝血时间，肝肾功能以及心绞痛发生频度、服用消心痛片数的变化。结果：天新利搏和ｔｉｃｌｏｐｉｄｉｎｅ与安慰剂相比对ＡＤＰ诱发的血小板聚集率具有相似的显著抑制作用（Ｐ＜００１）。Ａ组同时显示ＴＸＢ２Ｔ／Ｐ较服药前有显著下降（Ｐ＜００５）。结论：天新利博对冠心病血小板聚集率增高的患者具有显著的抗血小板聚集药效，并可改善患者的心绞痛症状，不良反应轻微，与ｔｉｃｌｏｐｉｄｉｎｅ具有相似的疗效。
OBJECTIVE: To compare the effect of domestic tianlibo and ticlopidine on the rate of platelet aggregation in patients with coronary heart disease and its effect on angina pectoris. Methods: 50 cases of stable angina pectoris, double-blind randomized parallel control method. Group A was given 250mg levamisole, group B received ticlopidine 250mg, group C took placebo, both with breakfast. Before and after taking the medicine, the ADP (05mol / L, 10mol / L) induced platelet aggregation rate, 6KetoPGF12, TXB2, blood Rt, the clotting time, liver and kidney function and the incidence of angina pectoris, The change. RESULTS: Tenoxifene and ticlopidine had similar inhibitory effects on ADP-induced platelet aggregation compared with placebo (P <001). Group A also showed that TXB2T / P decreased significantly compared with that before treatment (P <005). CONCLUSION: Tianxinlibo has significant anti-platelet aggregation effect on patients with elevated platelet aggregation rate of coronary heart disease, and can improve angina pectoris symptoms in patients with mild adverse reactions and has similar curative effect with ticlopidine.